Georgina Kilfoil has over thirty years of experience with a proven track record in building, growing, and financing life-science ventures with specific expertise in strategic drug development, operational project management, and clinical plan execution. Over the past twenty years, Georgina has been involved with—and in some cases led the development behind—several marketed anti-infectives including doripenem (Doribax®, Janssen), ceftolozane/tazobactam (Zerbaxa®, Merck), ceftaroline (Teflaro®, AbbVie), and anidulafungin (Eraxis®, Pfizer).

Georgina is a certified Project Management Professional, has a Bachelor of Science (Hons) in Pharmacology from the University of Bristol (UK) and an MBA from the Australian Graduate School of Management in Sydney, Australia.